Nasal COVID-19 vaccine approved in India based on Washington University technology

Sept. 12, 2022
Inhaled vaccine may reduce infection, transmission.

A nasal vaccine for COVID-19 – based on technology licensed from Washington University in St. Louis – was approved Tuesday, Sept. 6, in India for emergency use. Since the vaccine is delivered via the nose, right where the virus enters the body, it has the potential to block infection and break the cycle of transmission, as well as prevent lung damage.

Washington University scientists developed the nasal vaccine in collaboration with Bharat Biotech International Limited in India, a global leader in vaccine innovation and a developer of vaccines for infectious diseases.

Early studies at Washington University showed that nasal delivery of this vaccine creates a strong immune response throughout the body, especially in the nose and respiratory tract. In animal studies, the nasal vaccine prevented infection from taking hold in the body. While injectable COVID-19 vaccines have been shown to elicit protection against severe disease, this route of administration is thought to be less effective at preventing infection and possibly transmission.

Washington University in St. Louis release